Indications
Treatment of adults with of neovascular (wet) age-related macular degeneration (AMD), visual impairment and other retinopathies
Composition
- Active substance
- ranibizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vislyfa
- Active substance
- ranibizumab
- ATC code
- S01LA04
- Group
- Sensory organs
- Therapeutic area
- Wet Macular Degeneration, Macular Edema, Diabetes Complications, Retinal Vein Occlusion, Choroidal Neovascularization
- Marketing authorisation holder
- Lupin Europe GmbH
- Status
- CHMP opinion
- EMA product number